Abstract 168P
Background
Routine genomic profiling in metastasic solid tumors has an impact on survival by selecting targeted therapies and montoring treatment response. Moreover, feasibility and efficiency of liquid biopsy (LB) in pancreatic cancer has been studied as tissue is not always available in these tumors given the frequent lack of tissue in these tumors.
Methods
We present an ambispective observational study in patients with locally advanced or metastatic pancreatic cancer who underwent LB before starting chemotherapy. The primary end point was to determine the prevalence of pathological molecular alterations in circulating tumor DNA (ctDNA) and their concordance with next generation sequencing in tumor tissue (TNGS). A secondary end point was the study of circulating tumor cells (CTCs) as a poor prognostic factor for survival.
Results
A total of 30 patients were included between May 2020 and September 2022. Women were 53.3% of them, and the median age was 65.5 years (37-85). At the time of LB, 86.7% had metastatic disease, 6.7% had stage III, and 6.7% had stage II. 83.4% were about to initiate a first-line chemotherapy. 86.7% of the patients had also undergone TNGS. In both LB and TNGS, one or more molecular alterations were found in 80% of patients. Fourteen different molecular alterations were found in LB, with the most prevalent mutations in TP53 (56.6%), KRAS (53.3%), ERBB2 (16.6%), MET (4%), and EGFR (4%). In TNGS, 12 alterations were found, with the most prevalent being TP53 (46.6%), KRAS (60%), MET (23.3%), and EGFR (13.3%). The concordance rate between BL and TNGS was > 70%. The median overall survival (OS) was 5.5 months (95%CI:3.6-7.4). In patients without CTCs, the OS was 6.3 months (95%CI:4.7-8.0), while patients with CTCs had an OS of 3.6 months (95%CI:1.6-5.6).
Conclusions
80% of patients presented molecular alterations in both LB and TNGS with a matching rate > 70%. The most prevalent mutations were TP53, KRAS, MET, EGFR and ERBBE in the two analyses. The presence of CTCs is a poor prognostic factor.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract